Latest / Cyrona Cell Podcast: Stem Cell Therapy in Malaysia / Stem Cell Therapy for Type 2 Diabetes: Can It Improve Blood Sugar Control and Insulin Response?
Transcript
- 0:00SPEAKER_01: Welcome to the Sorona Cell podcast.
- 0:02SPEAKER_00: Thank you.
- 0:02SPEAKER_00: It's great to be here for this.
- 0:04SPEAKER_01: Right now, inside uh millions of people, there's basically a microscopic shouting match happening.
- 0:10SPEAKER_00: Yeah, that's a good way to put it.
- 0:11SPEAKER_01: Like the pancreas is screaming at the body to absorb sugar, and the body is just completely ignoring it.
- 0:17SPEAKER_00: Right, completely shutting it out.
- 0:19SPEAKER_01: And if you or you know, maybe someone you love is managing type 2 diabetes, you know exactly what the fallout of that shouting match looks like.
- 0:27SPEAKER_00: Absolutely.
- 0:27SPEAKER_00: It's exhausting.
- 0:28SPEAKER_01: It really is.
- 0:29SPEAKER_01: It's that daily just grinding calculus of diet, you know, the rigidly scheduled exercise, the endless alarms for medications.
- 0:38SPEAKER_01: You're basically acting as your body's manual override, just trying to keep your blood sugar steady.
- 0:43SPEAKER_00: Aaron Powell And that manual override is incredibly taxing on you.
- 0:47SPEAKER_00: I mean, even when you're strictly following all the rules and doing the math correctly, the underlying condition can still progress.
- 0:54SPEAKER_01: Aaron Powell Right, because you're just treating the surface level.
- 0:56SPEAKER_00: Aaron Powell Exactly.
- 0:57SPEAKER_00: You're managing the symptoms, but the environment inside the body remains, well, highly stressed.
- 1:03SPEAKER_00: And that ongoing deterioration is arguably the most frustrating part of the whole diagnosis.
- 1:08SPEAKER_01: Aaron Powell, which is exactly why so many people start looking beyond that standard routine.
- 1:11SPEAKER_01: You search the internet for better options, and uh you inevitably stumble onto something that sounds either incredibly futuristic or maybe a little too good to be true.
- 1:22SPEAKER_01: Gem cell therapy.
- 1:23SPEAKER_01: Gem cell therapy, exactly.
- 1:24SPEAKER_01: So the mission for today's deep dive is to cut straight through all that internet hype.
- 1:30SPEAKER_00: Which there's a lot of so much.
- 1:32SPEAKER_01: We are going to look at the practical science-based facts of modern cell-based support for studier glucose control.
- 1:39SPEAKER_01: And specifically, we're looking at how this is being utilized at CironaCell, which is a doctor-led regenerative medicine center based in Kuala Lumpur, Malaysia.
- 1:47SPEAKER_00: Aaron Powell It's a really fascinating area of medicine, but to your point, it is surrounded by just an enormous amount of noise.
- 1:52SPEAKER_01: Oh, yeah.
- 1:53SPEAKER_00: So if we want to actually understand how cellular support works, we have to ground this in the biology of what is happening inside a diabetic body first.
- 2:01SPEAKER_01: Aaron Powell Right.
- 2:02SPEAKER_01: We can't talk about the solution until we really get the problem.
- 2:05SPEAKER_00: Exactly.
- 2:06SPEAKER_00: We can't talk about the intervention until we understand the environment it's entering.
- 2:09SPEAKER_01: Aaron Powell So let's set that stage then.
- 2:11SPEAKER_01: Because there is a pretty fundamental difference between type 1 and type 2 diabetes, right?
- 2:17SPEAKER_01: And that dictates why this specific therapy is even an option.
- 2:21SPEAKER_00: Aaron Powell Yes, that distinction is critical.
- 2:23SPEAKER_01: Aaron Powell Because in type one, the body's immune system is mistakenly attacking its own insulin-producing cells.
- 2:30SPEAKER_01: It's an autoimmune condition.
- 2:32SPEAKER_00: Right, which requires a completely different specialist pathway.
- 2:35SPEAKER_01: Right.
- 2:36SPEAKER_00: Yeah.
- 2:36SPEAKER_01: But in type two, the dynamic is entirely different.
- 2:39SPEAKER_01: The body is actually still manufacturing insulin.
- 2:42SPEAKER_00: Exactly.
- 2:42SPEAKER_00: In type two diabetes, your pancreas is still producing insulin.
- 2:46SPEAKER_00: The problem is that your body is struggling to use it effectively.
- 2:49SPEAKER_01: It's just not listening.
- 2:50SPEAKER_00: Right.
- 2:50SPEAKER_00: This is what we call insulin resistance.
- 2:52SPEAKER_00: And over time, you develop this compounding systemic issue.
- 2:57SPEAKER_00: You have ongoing inflammation.
- 2:59SPEAKER_00: You often have extra visceral fat, that deep belly fat, which actually it acts almost like an active organ.
- 3:05SPEAKER_01: Wait, visceral fat acts like an organ?
- 3:07SPEAKER_00: It does, yeah.
- 3:08SPEAKER_00: It pumps out even more inflammatory signals into your bloodstream.
- 3:12SPEAKER_00: So all of this creates an environment where your cells essentially just stop listening to the insulin.
- 3:18SPEAKER_01: Okay, so I always used to picture this like a factory, but looking through our sources today, that metaphor kind of falls apart.
- 3:24SPEAKER_01: Because the insulin isn't the worker, the insulin is the key.
- 3:27SPEAKER_00: Right.
- 3:27SPEAKER_01: So let's try this.
- 3:29SPEAKER_01: Think of your body's cells as like a highly exclusive nightclub.
- 3:33SPEAKER_00: Okay, I like this.
- 3:34SPEAKER_01: And the glucose, the blood sugar, is the massive crowd trying to get in.
- 3:38SPEAKER_01: Insulin is the bouncer.
- 3:40SPEAKER_00: Perfect.
- 3:41SPEAKER_01: In a healthy body, the bouncer opens the door, the crowd goes in, and the street is clear.
- 3:46SPEAKER_01: But in type 2 diabetes, the doors to the club are basically rusted shut by inflammation.
- 3:51SPEAKER_00: Yes.
- 3:52SPEAKER_01: The bouncer is yelling, you know, pulling on the handle, but the door won't budge, and the crowd is just backing up into the street, which represents your rising blood sugar levels.
- 4:00SPEAKER_00: I actually prefer that to the factory analogy.
- 4:02SPEAKER_00: I really do.
- 4:03SPEAKER_00: Because it highlights the mechanism of the resistance.
- 4:06SPEAKER_00: The bouncer is doing his job, but the structural environment, the rusted door, is feeling him.
- 4:11SPEAKER_01: It's broken.
- 4:12SPEAKER_00: Right.
- 4:13SPEAKER_00: And because the sugar isn't clearing from the blood, your pancreas senses that backup.
- 4:19SPEAKER_00: So what does it do?
- 4:20SPEAKER_01: It probably sends more bouncers.
- 4:22SPEAKER_00: Exactly.
- 4:22SPEAKER_00: It assumes there aren't enough bouncers.
- 4:24SPEAKER_00: So it works harder, pumping out more and more insulin to try and force those doors open and overcome the resistance.
- 4:31SPEAKER_01: And eventually the manager sending out the bouncers just burns out.
- 4:34SPEAKER_00: Yeah, completely.
- 4:35SPEAKER_01: The pancreas gets exhausted from the constant overproduction, which is why patients often have to, you know, keep adding more tablets over the years, or eventually move to insulin injections just to keep the street clear.
- 4:46SPEAKER_00: Because the entire metabolic system is under immense chronic strain.
- 4:50SPEAKER_00: The beta cells in the pancreas, which manufacture the insulin, are literally working themselves to death.
- 4:56SPEAKER_01: Wow.
- 4:57SPEAKER_01: So how do stem cells actually intervene in this nightclub scenario?
- 5:01SPEAKER_01: Because the immediate assumption most people make is that we are talking about a whole organ replacement.
- 5:06SPEAKER_00: Oh, right.
- 5:06SPEAKER_01: Like are we just putting in a brand new pancreas or a completely new set of bouncers?
- 5:11SPEAKER_00: No, no.
- 5:12SPEAKER_00: And that is a common misconception that requires immediate correction.
- 5:16SPEAKER_00: The approach used at clinics like Cyrona Cell is not about replacing the organ.
- 5:21SPEAKER_01: Okay, so what is it doing?
- 5:23SPEAKER_00: It utilizes these cells as what we can best describe as microscopic support units.
- 5:29SPEAKER_00: They are not there to digest the sugar or act as insulin.
- 5:32SPEAKER_01: Okay, well, if they aren't digesting the sugar, what is their actual function when they get deployed into the bloodstream?
- 5:38SPEAKER_00: When these support units are introduced into the body, they travel systemically.
- 5:43SPEAKER_00: Their primary function is communication and environmental modulation.
- 5:47SPEAKER_01: Environmental modulation, so they're changing the scene.
- 5:50SPEAKER_00: Exactly.
- 5:50SPEAKER_00: They release highly specific anti-inflammatory signals aimed at calming down that systemic inflammation we just talked about.
- 5:57SPEAKER_01: Right, the rust on the doors.
- 5:58SPEAKER_00: Yes.
- 5:59SPEAKER_00: And they also support angiogenesis, which is the formation of new blood vessels, thereby improving blood flow to tissues that have been suffocating under all that metabolic stress.
- 6:09SPEAKER_01: Aaron Powell So going back to our nightclub, they aren't replacing the bouncer.
- 6:12SPEAKER_01: They are essentially acting as the maintenance crew.
- 6:15SPEAKER_00: Aaron Powell That's a great way to look at it.
- 6:17SPEAKER_01: They are applying like WD40 to the rusted hinges on the doors, calming down the immediate environment so that the existing bouncer can finally just do his job again.
- 6:27SPEAKER_00: Aaron Powell That is the biological goal, yes.
- 6:29SPEAKER_00: They are supporting the body's internal balance.
- 6:31SPEAKER_00: What we call homeostasis.
- 6:33SPEAKER_01: Homeostasis, right.
- 6:34SPEAKER_00: By changing the inflammatory environment, they help the body respond better to its own insulin.
- 6:38SPEAKER_00: It's a supportive role aimed at reducing that pancreatic stress response and improving overall insulin sensitivity.
- 6:45SPEAKER_01: Aaron Powell Okay.
- 6:46SPEAKER_01: So if these cells are acting as microscopic maintenance crews, the immediate question you, the listener, are probably asking right now is about the sourcing.
- 6:54SPEAKER_00: Of course.
- 6:55SPEAKER_01: Because the phrase stem cells carries, well, a lot of cultural baggage.
- 6:59SPEAKER_00: It really does.
- 7:00SPEAKER_01: People immediately picture controversial embryonic research or some experimental, unregulated science fiction cloning setup.
- 7:06SPEAKER_00: Right, so mad scientist lab.
- 7:08SPEAKER_01: Exactly.
- 7:09SPEAKER_01: We really need to look at where these cells actually come from.
- 7:11SPEAKER_00: Aaron Powell Well, the ethical sourcing is paramount.
- 7:13SPEAKER_00: Yeah.
- 7:14SPEAKER_00: And this is an area where Cirona cell operates under a very strict, highly transparent framework.
- 7:20SPEAKER_00: They do not use embryonic stem cells.
- 7:22SPEAKER_00: They do not use experimental chloropotent stem cells, which, by the way, are cells that can turn into any pushy type and are incredibly difficult to control.
- 7:31SPEAKER_01: They could just go rogue.
- 7:33SPEAKER_00: Exactly.
- 7:33SPEAKER_00: Instead, they utilize human umbilical cord-derived cells, specifically Wharton's jelly mesenchymal stem cells, often abbreviated as WJMSCCs.
- 7:44SPEAKER_01: Let's decode that for a second.
- 7:46SPEAKER_01: Wharton's jelly makes sense.
- 7:47SPEAKER_01: It's the protective gelatinous tissue within the umbilical cord.
- 7:50SPEAKER_01: Right.
- 7:51SPEAKER_00: Correct.
- 7:51SPEAKER_01: And these are sourced from donated cords after healthy, full-term deliveries with full maternal consent.
- 7:57SPEAKER_00: Aaron Powell Yes, entirely ethical and consented.
- 7:59SPEAKER_01: But what does the mesenchymal part mean?
- 8:01SPEAKER_01: Like why that specific type of cell?
- 8:04SPEAKER_00: Aaron Powell So mesenchymal refers to multipotent stromal cells that can differentiate into a variety of cell types, primarily connective tissues.
- 8:11SPEAKER_00: Okay.
- 8:12SPEAKER_00: But their real superpower, especially in the aerotherapeutic context, isn't necessarily what they turn into, but rather what they secrete.
- 8:18SPEAKER_00: Trevor Burrus, Jr.
- 8:18SPEAKER_01: What they release into the body.
- 8:20SPEAKER_01: Aaron Powell Right.
- 8:20SPEAKER_00: Mesenchymal stem cells are essentially the body's master signaling cells.
- 8:24SPEAKER_00: They are naturally highly anti-inflammatory and possess strong immunomodulatory properties.
- 8:30SPEAKER_01: Trevor Burrus Immunomodulatory.
- 8:32SPEAKER_01: Meaning they regulate the immune system.
- 8:34SPEAKER_00: Exactly.
- 8:34SPEAKER_00: It means they can help regulate a hyperactive or stressed immune system.
- 8:37SPEAKER_01: Aaron Ross Powell Which makes them the perfect candidate to send into a highly inflamed, stressed-out diabetic environment.
- 8:43SPEAKER_01: Trevor Burrus.
- 8:44SPEAKER_01: But you know, you are taking cellular material from one place, a donated umbilical cord culturing it, and putting it into another human being.
- 8:51SPEAKER_01: Yes.
- 8:52SPEAKER_01: And looking at the sources for Cyrinus cell, there is an absolute alphabet soup of certifications.
- 8:58SPEAKER_01: Oh, there is I see uh BSL2 laboratory standards, early passage cell, CGMP, ISO 9001.
- 9:05SPEAKER_01: Honestly, to a layman, that just looks like a Wi-Fi password.
- 9:08SPEAKER_00: Aaron Powell It does look like a random string of letters.
- 9:10SPEAKER_01: Yeah.
- 9:10SPEAKER_01: So what does this actually mean for the patient sitting in the chair looking at an IV bag?
- 9:14SPEAKER_00: Well, it means the exact opposite of a backroom unregulated clinic.
- 9:18SPEAKER_00: Let's break those down.
- 9:19SPEAKER_01: Yeah.
- 9:19SPEAKER_00: BSL2 stands for Biosafety Level 2, which dictates rigorous facility safeguards for handling human cells.
- 9:26SPEAKER_01: Okay, so it's a very secure lab.
- 9:27SPEAKER_00: Aaron Ross Powell Right.
- 9:28SPEAKER_00: And CGMP is crucial.
- 9:30SPEAKER_00: It stands for current good manufacturing practice.
- 9:33SPEAKER_00: This is a regulatory standard that guarantees the product is consistently produced and controlled according to strict quality standards.
- 9:40SPEAKER_01: Meaning they aren't just guessing what's in the bag?
- 9:43SPEAKER_00: Far from it.
- 9:44SPEAKER_00: Before any batch of cells is released to the clinical floor, it goes through exhaustive checks for identity, sterility, and viability.
- 9:51SPEAKER_01: Wow.
- 9:51SPEAKER_01: So they really test every single batch.
- 9:54SPEAKER_00: They have to.
- 9:55SPEAKER_00: They need absolute certainty that the IV bag is completely sterile, that it contains the exact cell count promised, and most importantly, that those cells are robust and biologically active.
- 10:05SPEAKER_01: And what about that early passage term?
- 10:08SPEAKER_00: Ah, early passage means the cells haven't been aggressively multiplied in a lab to the point of exhaustion.
- 10:14SPEAKER_00: They are young, potent, and ready to signal.
- 10:16SPEAKER_01: I see.
- 10:17SPEAKER_01: And our sources also mentioned something called exosomes, noting that Cirona cell offers exosome therapy as an added value.
- 10:23SPEAKER_00: Yes, exosomes are fascinating.
- 10:24SPEAKER_01: So if the mesenchymal stem cells are the maintenance crew, how do exosomes fit into this strategy?
- 10:30SPEAKER_00: Aaron Ross Powell Think of exosomes as the text messages or the instruction manuals that the maintenance crew uses to communicate.
- 10:36SPEAKER_01: Hex messages, okay.
- 10:37SPEAKER_00: Biologically, they are tiny extracellular vesicles, basically messenger packets released by the stem cells.
- 10:45SPEAKER_00: They are packed with helpful proteins, lipids, and genetic information like messenger RNA.
- 10:50SPEAKER_01: Aaron Powell So they're essentially the physical packages of those anti-inflammatory signals you mentioned earlier.
- 10:56SPEAKER_00: Yes.
- 10:57SPEAKER_00: By utilizing exosomes alongside the stem cells, you are flooding the stressed environment with a concentrated dose of these signals.
- 11:05SPEAKER_01: Aaron Ross Powell You're just boosting the signal.
- 11:07SPEAKER_00: Exactly.
- 11:07SPEAKER_00: It amplifies the communication, further calming the inflammation and instructing the stressed cells on how to repair themselves.
- 11:14SPEAKER_01: Aaron Powell That structural protective approach actually mirrors the clinic's namesake.
- 11:18SPEAKER_01: I was reading that Sirona is named after a Celtic goddess of health and protection.
- 11:22SPEAKER_00: Oh, that's right.
- 11:23SPEAKER_01: Yeah, and it feels very aligned with their philosophy.
- 11:25SPEAKER_01: Like they are offering a highly regulated protective intervention rather than an exaggerated overnight fix.
- 11:32SPEAKER_00: And that emphasis on structure and safety over sensationalism is a hallmark of legitimate regenerative medicine.
- 11:39SPEAKER_01: Aaron Powell Which brings up the most important question, I think.
- 11:42SPEAKER_01: The biology of these cellular text messages and maintenance crews makes perfect logical sense on a whiteboard.
- 11:48SPEAKER_01: Sure.
- 11:48SPEAKER_01: But how does it translate to a real human being with type 2 diabetes?
- 11:52SPEAKER_01: I really want to look at the human data here.
- 11:54SPEAKER_00: Let's do it.
- 11:55SPEAKER_01: So I was reviewing the Shandong University study from our sources, and it fascinated me because they saw tangible blood sugar improvements in adults who received umbilical cord MSC infusions.
- 12:05SPEAKER_00: Big age.
- 12:06SPEAKER_01: But my immediate skeptic brain says, um, injecting foreign cells into your bloodstream must cause some kind of reaction, right?
- 12:13SPEAKER_01: What actually happens?
- 12:15SPEAKER_00: Well, it does cause a biological reaction, and the Shandong studies are really great example of transparent reporting.
- 12:21SPEAKER_00: They tracked the metabolic markers and noted improved blood sugar control in a subgroup of the patients.
- 12:26SPEAKER_01: Okay.
- 12:27SPEAKER_00: But they also reported mild short-term side effects in some participants, most commonly a temporary fever.
- 12:33SPEAKER_01: Wait, a fever?
- 12:34SPEAKER_01: Why a fever?
- 12:35SPEAKER_01: Is that the body rejecting the cells?
- 12:36SPEAKER_00: No, no, not a rejection at all.
- 12:38SPEAKER_00: The fever is actually a known transient biological response.
- 12:43SPEAKER_00: You're introducing millions of potent signaling cells into a highly inflamed environment.
- 12:50SPEAKER_01: So it's like a system shock.
- 12:51SPEAKER_00: Not a shock, more like the immune system is essentially saying hello to these new signals.
- 12:57SPEAKER_00: The body temperature rises slightly as the immune system interacts with the immunomodulatory effects of the MSEs.
- 13:03SPEAKER_01: Oh, I see.
- 13:04SPEAKER_00: Yeah, typically resolves quickly.
- 13:06SPEAKER_00: And it's a sign that the signaling process has begun, which subsequently leads to the supported insulin sensitivity they measured.
- 13:13SPEAKER_01: But a short-term study only tells us so much, you know?
- 13:16SPEAKER_01: You really want to know what happens a year or two down the line.
- 13:19SPEAKER_01: Absolutely.
- 13:19SPEAKER_01: And that's why the Kingdao University study caught my eye, because this was a randomized controlled study, which is the gold standard, using Wharton's jelly-derived cells.
- 13:28SPEAKER_01: And they followed the patients for up to 36 months.
- 13:31SPEAKER_01: I mean, three years is a massive window in clinical research.
- 13:34SPEAKER_00: It really is.
- 13:35SPEAKER_00: And it provides invaluable data on longevity and safety.
- 13:38SPEAKER_00: Over those 36 months, they reported a stable safety profile, meaning there were no adverse long-term effects or dangerous complications from the cellular infusions.
- 13:47SPEAKER_01: And what about their daily diabetes management during those three years?
- 13:51SPEAKER_00: Well, compared to the control group, the treatment group showed sustained improvements in their glykemic markers.
- 13:56SPEAKER_00: Yeah.
- 13:57SPEAKER_00: A key metric here is HBA1C.
- 13:59SPEAKER_01: Right, that's the long-term blood sugar average.
- 14:02SPEAKER_00: Exactly.
- 14:02SPEAKER_00: It's a blood test that measures your average blood sugar levels over the past three months.
- 14:06SPEAKER_00: It gives a much better picture of long-term control than a daily finger prick.
- 14:10SPEAKER_01: Makes sense.
- 14:11SPEAKER_00: The patients receiving the cells saw better HBA1C stabilization.
- 14:16SPEAKER_00: Now, biological responses are never a monolith.
- 14:19SPEAKER_00: Results naturally vary between individuals based on their starting health, but the overall trend over three years was a highly positive stabilization.
- 14:27SPEAKER_01: Okay, so hearing these results sustained HBA1C improvements, a three-year stable safety profile, I have to push back a little bit on behalf of the listener.
- 14:36SPEAKER_00: Please do.
- 14:37SPEAKER_01: Someone grinding through their daily medication alarms is hearing this and thinking, you know, is this the cure I've been waiting for?
- 14:44SPEAKER_00: And the answer to that is an emphatic, unequivocal no.
- 14:47SPEAKER_01: No.
- 14:48SPEAKER_00: No.
- 14:48SPEAKER_00: At this current time, there is no proven definitive cure for type 2 diabetes.
- 14:54SPEAKER_00: And frankly, any provider, website, or clinic that promises you a cure should be viewed with extreme suspicion.
- 15:01SPEAKER_01: Red flags everywhere.
- 15:02SPEAKER_00: Absolutely.
- 15:02SPEAKER_00: Seronacell states very clearly in their literature that they do not offer a cure.
- 15:07SPEAKER_01: So how should a patient conceptually frame this therapy then?
- 15:10SPEAKER_01: If it's not a cure, what is the actual realistic expectation?
- 15:14SPEAKER_00: It must be framed as an adjunct therapy.
- 15:16SPEAKER_00: It is an advanced biological support tool.
- 15:19SPEAKER_00: The realistic goal is not to walk out of the clinic, throw away your metformin or your insulin, and eat a dozen donuts.
- 15:25SPEAKER_01: Right, it's not a free path.
- 15:26SPEAKER_00: Not at all.
- 15:27SPEAKER_00: The goal is steadier glucose control.
- 15:29SPEAKER_00: It is about smoothing out the curve, experiencing fewer of those sharp exhausting spikes and crashes in blood sugar.
- 15:35SPEAKER_01: Giving your body a break.
- 15:36SPEAKER_00: Yes.
- 15:37SPEAKER_00: It is about mitigating the long-term inflammatory damage to your organs, ultimately aiming for a vastly improved quality of life.
- 15:45SPEAKER_00: This therapy is designed to work in tandem with your doctor's existing plan, your nutrition, your physical activity, and your current medical management.
- 15:53SPEAKER_01: I think that transparency is just vital.
- 15:55SPEAKER_01: It shifts the entire conversation from some miraculous magic eraser to a highly sophisticated tool for metabolic management.
- 16:02SPEAKER_01: Exactly.
- 16:03SPEAKER_01: So let's look at the reality of the patient journey.
- 16:06SPEAKER_01: If someone is listening, perhaps they are in Australia or the Middle East, which uh are key service areas for Sarona Cell, and they decide to travel to Kuala Lumpur for this.
- 16:16SPEAKER_01: Who actually qualifies?
- 16:18SPEAKER_00: Patient selection is the single most critical step of the entire process.
- 16:22SPEAKER_00: Because to be entirely blunt, not everyone's going to benefit from this therapy.
- 16:26SPEAKER_01: Really?
- 16:26SPEAKER_00: Yeah.
- 16:27SPEAKER_00: SerenaCell employs a multidisciplinary medical team physicians from internal medicine, neurology, rehabilitation, and other specialties.
- 16:35SPEAKER_00: They conduct a rigorous evaluation of your medical history before you ever even book a flight.
- 16:40SPEAKER_01: Beyond just looking at the blood sugar numbers, what are those specialists actually screening for?
- 16:46SPEAKER_00: They evaluate the entirety of your metabolic health.
- 16:48SPEAKER_00: They look at your detailed diabetes history, your current HBA1C levels, your hepatic and renal function, meaning how well your liver and kidneys are handling the strain.
- 16:58SPEAKER_01: Right, looking at the whole system.
- 17:00SPEAKER_00: Exactly.
- 17:00SPEAKER_00: They analyze your current medication load, especially if you are heavily dependent on exogenous insulin.
- 17:07SPEAKER_00: They are essentially assessing the current state of that nightclub we talked about earlier.
- 17:12SPEAKER_01: Right.
- 17:12SPEAKER_01: Because if the building has completely burned to the ground, meaning the beta cells and the pancreas are entirely depleted and incapable of producing any insulin at all, sending in a maintenance crew won't really do anything.
- 17:24SPEAKER_00: Exactly.
- 17:25SPEAKER_00: Patients tend to see the most significant benefits when they still have a reserve of pancreatic function.
- 17:30SPEAKER_01: Okay, that makes sense.
- 17:31SPEAKER_00: If the beta cells are just struggling and suppressed by inflammation, the cellular support can make a profound difference.
- 17:39SPEAKER_00: But if the team evaluates your organ strain and remaining function and determines you are unlikely to see a clinical benefit, they will honestly tell you no.
- 17:48SPEAKER_01: I find immense comfort in that, honestly.
- 17:51SPEAKER_01: You aren't just a revenue stream or a number on a conveyor belt.
- 17:54SPEAKER_01: A clinic that is willing to turn away a paying patient because the science doesn't support the outcome is a clinic that is prioritizing long-term medical trust over short-term procedures.
- 18:05SPEAKER_00: It establishes a foundation of clinical integrity, which is essential when dealing with international patients seeking advanced care.
- 18:12SPEAKER_01: Okay, so let's assume you pass the screening.
- 18:14SPEAKER_01: You are a viable candidate with remaining pancreatic function.
- 18:17SPEAKER_01: You arrive in Kuala Lumpur.
- 18:19SPEAKER_01: What does the actual day of treatment entail?
- 18:21SPEAKER_01: Okay.
- 18:21SPEAKER_01: Because again, the phrase stem cell therapy makes people picture a sterile surgical theater, general anesthesia, and a lengthy recovery period.
- 18:28SPEAKER_00: Right, but the reality is much less dramatic.
- 18:30SPEAKER_00: The procedure itself is minimally invasive.
- 18:33SPEAKER_01: Minimally invasive.
- 18:34SPEAKER_00: Yes.
- 18:34SPEAKER_00: There is no open surgery, no bone marrow extraction from the patient, and no general anesthesia required for these standard protocols.
- 18:43SPEAKER_00: The heavy lifting has already been done in the BSL2 laboratory by the specialists who cultured and verified those WJMSEs.
- 18:50SPEAKER_01: So how do the cells get from the lab to the rusted hinges of the cells?
- 18:55SPEAKER_00: Through a standard intravenous or a VIV infusion.
- 18:58SPEAKER_01: Oh, just an IV?
- 18:59SPEAKER_00: Just an IV.
- 19:00SPEAKER_00: You are typically seated comfortably in a clinical treatment chair.
- 19:04SPEAKER_00: The prepared cells are delivered slowly into your bloodstream.
- 19:08SPEAKER_00: Because they are administered systemically, they travel through your circulatory system, naturally homing in on the areas of the body emitting the highest inflammatory distress signals.
- 19:17SPEAKER_01: That's incredible.
- 19:18SPEAKER_00: You simply sit and relax while the microscopic support units are introduced into your system.
- 19:22SPEAKER_01: It is essentially an advanced IV drip.
- 19:24SPEAKER_01: You could be, you know, reading a book, catching up on emails, or listening to a deep dive like this one while your body receives millions of anti-inflammatory signals.
- 19:33SPEAKER_00: Yeah, it is designed to be highly tolerable and straightforward for the patient.
- 19:37SPEAKER_01: But I imagine the clinical relationship doesn't just sever the moment the IV is removed.
- 19:41SPEAKER_01: If I'm flying back to the Middle East or Australia, how does a clinic in Malaysia manage my ongoing care?
- 19:47SPEAKER_00: Well, the post-infusion follow-up is a structured, long-term commitment.
- 19:52SPEAKER_00: Cironacelles medical and patient liaison teams track your outcomes rigorously.
- 19:57SPEAKER_01: Oh, so they keep in touch.
- 19:59SPEAKER_00: Absolutely.
- 20:00SPEAKER_00: They monitor your localized blood sugar reporting, track any transient side effects like that mild fever we discussed, and assess your overall metabolic well-being.
- 20:08SPEAKER_00: That's reassuring.
- 20:09SPEAKER_00: And more importantly, because this is an adjunct therapy, they actively coordinate with your local primary care physicians and endocrinologists back home.
- 20:17SPEAKER_01: They actually talk to your local doctors.
- 20:19SPEAKER_00: Yes, they want to ensure that your entire care ecosystem, your local dietitians, your standard medications, and the cellular intervention are fully integrated and working together over the months and years ahead.
- 20:30SPEAKER_01: Let's zoom out and lock in what we've unpacked today.
- 20:33SPEAKER_01: If you are locked in the daily exhausting grind of managing type 2 diabetes, stem cell therapy at Cirona Shell is not a magic overnight cure.
- 20:41SPEAKER_01: It is, however, a highly structured, scientifically backed adjunct therapy.
- 20:46SPEAKER_01: By utilizing ethically sourced, rigorously tested Wharton's jelly mesanchemel stem cells to act as metabolic support units, patients are given a modern biological tool to help calm systemic inflammation, unrest the cellular doors, and aim for far steadier glucose control.
- 21:03SPEAKER_00: That captures the reality perfectly.
- 21:05SPEAKER_00: It is about realistic, long-term biological support, deeply rooted in safety and rigorous laboratory standards.
- 21:12SPEAKER_01: And this matters to you, the listener, because it represents a profound shift in how modern medicine approaches chronic degenerative conditions.
- 21:19SPEAKER_00: A huge shift.
- 21:20SPEAKER_01: It's a shift from merely medicating the symptoms, just dealing with the crowds backed up on the street, to actually supporting the boder's underlying metabolic environment and fixing the cellular communication breakdown at the source.
- 21:32SPEAKER_00: It is a shift toward regenerative balance rather than just pharmacological management.
- 21:36SPEAKER_01: We've covered the biological mechanics, the rigorous sourcing, the long term human data, and the reality of the patient experience.
- 21:44SPEAKER_01: But before we sign off, I want to leave the listener with something new to chew on.
- 21:48SPEAKER_01: Based on everything we've discussed about how these cells operate, what is the big takeaway here?
- 21:53SPEAKER_00: Well, consider the mechanism we spent the most time on today the ability of these umbilical cord cells to seek out and dramatically.
- 22:02SPEAKER_01: Right.
- 22:03SPEAKER_00: We focused entirely on how that helps type 2 diabetes.
- 22:06SPEAKER_00: But if these microscopic support units are so exceptionally good at cooling down inflammatory fires and sending regenerative text messages, it makes you wonder what other chronic inflammatory conditions, from severe joint degeneration to complex autoimmune flare-ups, might be listening to those exact same cellular instructions.
- 22:24SPEAKER_01: Wow.
- 22:25SPEAKER_01: That is a fascinating thread to pull.
- 22:27SPEAKER_01: If the body uses one universal language for inflammation and repair, learning to speak that language could change how we approach almost every chronic condition we face.
- 22:36SPEAKER_01: Thank you for joining us on this deep dive.